| Identification | More | [Name]
Tenofovir | [CAS]
147127-20-6 | [Synonyms]
1-(6-aminopurin-9-yl)propan-2-yloxymethylphosphonic acid
D,L-TENOFOVIR
(R)-9-(2-PHOSPHONYLMETHOXYPROPYL)-ADENINE
TENOFOVIR
(R)-9-(2-Phosphonomethoxypropyl)Adenine
Tenofovir(ForResearchOnly)
(R)-PMPA
[[(1R)-2(6-Amino-9H-purin-9-yl)-1-methylethoxy]methyl]phosphonic Acid
GS-1278
Tenofovir disoproxil fumarate and intermediates
(R)-9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) | [EINECS(EC#)]
604-571-2 | [Molecular Formula]
C9H14N5O4P | [MDL Number]
MFCD07357269 | [Molecular Weight]
287.21 | [MOL File]
147127-20-6.mol |
| Chemical Properties | Back Directory | [Appearance]
White Crystalline Solid | [Melting point ]
276-280°C | [alpha ]
D +21° (c = 1 in 0.1M HCl) | [Boiling point ]
616.1±65.0 °C(Predicted) | [density ]
1.79±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
Aqueous Acid (Sparingly), DMSO (Slightly, Heated), Water (Slightly, Heated) | [form ]
powder | [pka]
2.36±0.10(Predicted) | [color ]
white to beige | [optical activity]
[α]/D -20 to -26°, c = 0.5 in 1 M HCl | [Water Solubility ]
13.4 mg/mL (25 ºC) | [Usage]
Acyclic phosphonate nucleotide analogue. Used as an anti-HIV agent | [Merck ]
14,9146 | [InChI]
InChI=1S/C9H14N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17)/t6-/m1/s1 | [InChIKey]
SGOIRFVFHAKUTI-ZCFIWIBFSA-N | [SMILES]
P(CO[C@H](C)CN1C2C(N=C1)=C(N)N=CN=2)(=O)(O)O | [CAS DataBase Reference]
147127-20-6(CAS DataBase Reference) |
| Questions And Answer | Back Directory | [Uses]
Tenofovir is an acyclic phosphonate nucleotide analogue and reverse transcriptase inhibitor. It is used as an anti-HIV agent. Antiviral. | [Indications and Usage]
Tenofovir disoproxil (Viread) is the first nucleotide analogue approved by the American FDA to treat HIV-1 infections. Tenofovir disoproxil is a drug used in the AIDS cocktail treatment method, and research shows that it has the ability to increase monkeys’ immunity to immunodeficiency viruses (similar to the human AIDS virus). Tenofovir disoproxil is used in combination with other reverse transcriptase inhibitors to treat HIV-1 infections and hepatitis B.
| [Mechanisms of Action]
Tenofovir disoproxil is an acyclic nucleoside antivirus drug and has an inhibiting effect on HBV multi-enzyme complexes and HIV reverse transcriptase. Its active content tenofovir phosphonate directly competitively binds to natural deoxyribose substrate to inhibit the virus multi-enzyme complex and inserts itself into the DNA to end the nucleotide chain. Tenofovir disoproxil is barely absorbed by the gastrointestinal duct, so it undergoes esterification and ionization to become tenofovir ester fumarate. Tenofovir is soluble in water and can be quickly absorbed and decomposed into the active substance tenofovir, which then transforms into the active metabolite tenofovir phosphonate. As this drug is not metabolized by the CYP450 enzyme system, it has a very low chance of drug interactions caused by this enzyme.
| [Pharmacokinetics]
Tenofovir disoproxil reaches peak blood concentration 1-2 hours after intake. Tenofovir disoproxil’s bioavailability increases by about 40% when taken with food. The intracellular half-life of tenofovir phosphonate is about 10 hours, so doses can be taken once daily. This drug is mainly filtered through renal glomeruli and excreted through the renal tubule transport system, with 70-80% excreted in its original form through urine.
| [Adverse Effects]
- Weakness and exhaustion.
- Mild to moderate gastrointestinal reactions, including diarrhea, stomach pain, nausea, vomiting, bloating, lactic acid poisoning, hepatomegaly and fatty liver, and pancreatitis. These adverse reactions also commonly appear individually or combined when taking nucleoside analogues.
- Metabolic system hypophosphatemia (1% occurrence rate).
- Fat accumulation and redistribution, including centripetal obesity, buffalo hump, thin limbs, breast growth, and Cushing syndrome.
- May cause lactic acid poisoning, hepatomegaly related to steatosis, etc.
- Effects on nervous system: dizziness and headache.
- Effects on respiratory system: difficulty breathing.
- Effects on skin: drug rash.
|
| Hazard Information | Back Directory | [Description]
Tenofovir is an analog of adenosine monophosphate that has antiviral activity.1,2 It is converted by cellular enzymes to tenofovir diphosphate, an obligate chain terminator that inhibits the activity of HIV reverse transcriptase and hepatitis B virus polymerase.3,4 Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases α and β and mitochondrial DNA polymerase γ.4 For in vivo and cell culture use, tenofovir is supplied as a water soluble prodrug in the form of tenofovir disoproxil (fumarate) (Item No. 16922), which increases the intracellular diphosphorylated compound >1,000-fold above the level attained with unmodified tenofovir.4 | [Chemical Properties]
White Crystalline Solid | [Definition]
ChEBI: A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxy
ethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection. | [Indications]
Tenofovir disoproxil fumarate (Viread) is a prodrug of
tenofovir, a phosphorylated adenosine nucleoside analogue,
and is the only available agent of its class. It is
converted by cellular enzymes to tenofovir diphosphate,
which competes with deoxyadenosine triphosphate
(dATP) for access to reverse transcriptase and
causes chain termination following its incorporation.
Tenofovir was approved as part of a combination therapy
for HIV in adults who failed treatment with other
regimens; it appears to be effective against HIV strains
that are resistant to NRTIs. | [Acquired resistance]
HIV variants with the K65R mutation and the K70E mutation
in the reverse transcriptase demonstrate reduced susceptibility
to tenofovir. | [Pharmaceutical Applications]
A nucleotide analog structurally similar to adefovir.
EC50 values for HBV, assessed in the HepG2 2.2.15 cell
line, ranged from 0.14 to 1.5 μm; the cytotoxic concentration
exceeded 100 μm. A decline in HBV DNA levels below
105 copies/mL at 48 weeks of therapy in 100% of patients
receiving tenofovir compared with 44% on adefovir therapy
has been reported. There are also case reports of patients with
primary resistance to adefovir responding to tenofovir.
It is generally well tolerated in patients with chronic HBV;
the most common side effects include nausea and gastrointestinal
upset, headache, dizziness, fatigue and rash. | [Pharmaceutical Applications]
An acyclic nucleoside phosphonate, formulated as the disoproxil
fumarate salt for oral administration. | [Biological Activity]
Selectively inhibits HIV reverse transcriptase (RNA-dependent DNA polymerase). Prevents cytotoxicity in SIV-infected C-8166 cells in vitro (IC 50 = 1.5 μ M). Antiviral agent. | [Biochem/physiol Actions]
Tenofovir has a low oral bioavailability. Hence, it is available as a prodrug called tenofovir disoproxil fumarate. Once ingested, tenofovir disoproxil fumarate is hydrolyzed to tenofovir and phosphorylated. This is then incorporated into the viral DNA which leads to chain termination. Tenofovir is also effective against hepatitis B virus. | [Clinical Use]
Chronic hepatitis B infection | [Clinical Use]
Treatment of HIV infection in adults and children (in combination with
other antiretroviral drugs) | [Side effects]
In clinical trials of antiretroviral treatment-naive participants,
the most commonly reported adverse events were mild to
moderate gastrointestinal upset (nausea 8%, diarrhea 11%),
headache (14%) and depression (11%). Tenofovir has the
potential to result in nephrotoxicity, particularly through proximal
tubular damage, but the risk of clinically significant renal
dysfunction appears relatively low and seems to occur mainly
in subjects with other identifiable risks for renal impairment.
Minor elevations in serum creatinine and reductions in creatinine
clearance occur, but rarely require drug discontinuation.
A few (<0.1%) cases of osteomalacia and decreased bone
density have been reported. | [Side effects]
Tenofovir is taken once daily and is generally well
tolerated, perhaps because it produces less mitochondrial
toxicity than the NRTIs. Nausea, vomiting, flatulence,
and diarrhea occur in 10% or fewer patients.
Resistance to tenofovir has been documented, and
cross-resistance to NRTIs may occur. | [storage]
Store at -20°C |
|
|